Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk.
association study
genetic susceptibility
pancreatic ductal adenocarcinoma
single nucleotide polymorphisms
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 07 2023
15 07 2023
Historique:
revised:
14
09
2022
received:
12
05
2022
accepted:
06
10
2022
medline:
15
5
2023
pubmed:
2
12
2022
entrez:
1
12
2022
Statut:
ppublish
Résumé
Genes carrying high-penetrance germline mutations may also be associated with cancer susceptibility through common low-penetrance genetic variants. To increase the knowledge on genetic pancreatic ductal adenocarcinoma (PDAC) aetiology, the common genetic variability of PDAC familial genes was analysed in our study. We conducted a multiphase study analysing 7745 single nucleotide polymorphisms (SNPs) from 29 genes reported to harbour a high-penetrance PDAC-associated mutation in at least one published study. To assess the effect of the SNPs on PDAC risk, a total of 14 666 PDAC cases and 221 897 controls across five different studies were analysed. The T allele of the rs1412832 polymorphism, that is situated in the CDKN2B-AS1/ANRIL, showed a genome-wide significant association with increased risk of developing PDAC (OR = 1.11, 95% CI = 1.07-1.15, P = 5.25 × 10
Substances chimiques
RNA, Long Noncoding
0
CDKN2B antisense RNA, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
373-379Informations de copyright
© 2022 UICC.
Références
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778-789.
Lu Y, Gentiluomo M, Lorenzo-Bermejo J, et al. Mendelian randomisation study of the effects of known and putative risk factors on pancreatic cancer. J Med Genet. 2020;57(12):820-828.
Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493-502.
Gentiluomo M, Canzian F, Nicolini A, Gemignani F, Landi S, Campa D. Germline genetic variability in pancreatic cancer risk and prognosis. Semin Cancer Biol. 2022;79:105-131.
Galeotti AA, Gentiluomo M, Rizzato C, et al. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. J Med Genet. 2020;58:369-377.
Lu Y, Gentiluomo M, Macauda A, et al. Identification of recessively inherited genetic variants potentially linked to pancreatic cancer risk. Front Oncol. 2021;11:771312.
Zhang YD, Hurson AN, Zhang H, et al. Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. Nat Commun. 2020;11(1):3353.
Pistoni L, Gentiluomo M, Lu Y, et al. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Carcinogenesis. 2021;42(8):1037-1045.
Corradi C, Gentiluomo M, Gajdán L, et al. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Int J Cancer. 2021;148(11):2779-2788.
Lu Y, Corradi C, Gentiluomo M, et al. Association of genetic variants affecting microRNAs and pancreatic cancer risk. Front Genet. 2021;12:693933.
Kleiblova P, Stolarova L, Krizova K, et al. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer. Int J Cancer. 2019;145(7):1782-1797.
Read J, Wadt KAW, Hayward NK. Melanoma genetics. J Med Genet. 2016;53(1):1-14.
Campa D, Pastore M, Gentiluomo M, et al. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Oncotarget. 2016;7(35):57011-57020.
Campa D, Capurso G, Pastore M, et al. Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumors. Sci Rep. 2016;6:39565.
Akhter N, Dar SA, Haque S, et al. Crosstalk of cyclin-dependent kinase inhibitor 1A (CDKN1A) gene polymorphism with p53 and CCND1 polymorphism in breast cancer. Eur Rev Med Pharmacol Sci. 2021;25(12):4258-4273.
Bulgakova O, Kussainova A, Bersimbaev R. The cell cycle regulatory gene polymorphisms TP53 (rs1042522) and MDM2 (rs2279744) in lung cancer: a meta-analysis. Vavilovskii Zh Genet Sel. 2020;24(7):777-784.
Boujemaa M, Mighri N, Chouchane L, et al. Health influenced by genetics: a first comprehensive analysis of breast cancer high and moderate penetrance susceptibility genes in the Tunisian population. PLoS One. 2022;17(3):e0265638.
Zhang P, Kitchen-Smith I, Xiong L, et al. Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression, and drug response. Cancer Res. 2021;81(7):1667-1680.
Lin Y, Nakatochi M, Hosono Y, et al. Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Nat Commun. 2020;11(1):3175.
Campa D, Rizzato C, Capurso G, et al. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic disease ReseArch (PANDoRA) consortium. Dig Liver Dis. 2013;45(2):95-99.
GTEx Consortium. The genotype-tissue expression (GTEx) project. Nat Genet. 2013;45(6):580-585.
Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2012;40:D930-D934.
Boyle AP, Hong EL, Hariharan M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 2012;22(9):1790-1797.
Zhu B, Zhu Y, Tian J, et al. A functional variant rs1537373 in 9p21.3 region is associated with pancreatic cancer risk. Mol Carcinog. 2019;58(5):760-766.
Vaish U, Jain T, Are AC, Dudeja V. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma: an update on heterogeneity and therapeutic targeting. Int J Mol Sci. 2021;22(24):13408.
Zhao R, Choi BY, Lee M-H, Bode AM, Dong Z. Implications of genetic and epigenetic alterations of CDKN2A (p16[INK4a]) in cancer. EBioMedicine. 2016;8:30-39.
Campa D, Rizzato C, Bauer AS, et al. Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations. Cancer Epidemiol Biomarkers Prev. 2013;22(2):320-323.